Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1RA) such as liraglutide and semaglutide induce significantly greater weight loss and reduce hepatic fat content compared to lifestyle modification and first-generation anti-obesity drugs.
If you have obesity, Type 2 Diabetes, or fatty liver disease (MASLD), GLP-1 receptor agonists like semaglutide or liraglutide are currently the most effective pharmacological treatments for weight loss, outperforming lifestyle changes alone and older weight-loss drugs. They work by targeting brain centers to reduce appetite and also directly reduce liver fat. While they can cause side effects like nausea, their ability to improve metabolic health and liver disease makes them a superior option for many patients, though adherence to the regimen is critical.
Certain GLP-1RA are superior to lifestyle modification and first-generation anti-obesity drugs in inducing weight loss. They also lead to a reduction of hepatic fat content and inflammation in people with biopsy-confirmed MASLD.
Why this rating
Based on a review of extensive literature including meta-analyses of RCTs and clinical trials, though it is a review paper rather than a single primary trial.
Source
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou et al. · Alimentary Pharmacology & Therapeutics · 2024
DOI 10.1111/apt.17848
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →